AKT1 and non-small cell lung carcinoma: To investigate the role of AKT in 2-DG—mediated ERK inhibition, LKB1-WT NSCLC cells (H226, H522 and Calu-1) were pretreated with or without LY294002(LY), a small molecular inhibitor of PI3K, for 30 minutes before 2-DG treatment.